Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits
Name
1-s2.0-S2452302X20301704-main.pdf
Description
Published version
Size
1.5 MB
Format
Unknown
Checksum (MD5)
d08df68a92498bb150159110d47831fb
Author(s)
Chowdhury, Mohammed M
Singh, Kanwarpal
Albaghdadi, Mazen S
Khraishah, Haitham
Mauskapf, Adam
Kessinger, Chase W
Osborn, Eric A
Kellnberger, Stephan
Piao, Zhonglie
Lino Cardenas, Christian L
Date Issued
2020
Journal
JACC: Basic to Translational Science
Publisher
Elsevier BV
Version
Final published version
Abstract
© 2020 The Authors Paclitaxel drug-coated balloons (DCBs) reduce restenosis, but their overall safety has recently raised concerns. This study hypothesized that DCBs could lessen inflammation and reduce plaque progression. Using 25 rabbits with cholesterol feeding- and balloon injury-induced lesions, DCB-percutaneous transluminal angioplasty (PTA), plain PTA, or sham-PTA (balloon insertion without inflation) was investigated using serial intravascular near-infrared fluorescence−optical coherence tomography and serial intravascular ultrasound. In these experiments, DCB-PTA reduced inflammation and plaque burden in nonobstructive lesions compared with PTA or sham-PTA. These findings indicated the potential for DCBs to serve safely as regional anti-atherosclerosis therapy.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.JACBTS.2020.04.007
